Quick Answer
Protalix BioTherapeutics, Inc. reported Gross Profit of $4.01 million for fiscal year 2017.
Protalix BioTherapeutics, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2017 | $4.01M | +400.7% |
| 2016 | $801.0K | -78.0% |
| 2015 | $3.63M | +25.6% |
| 2014 | $2.89M | — |
| 2013 | $0.00 | -100.0% |
| 2012 | $26.28M | +1721.2% |
| 2011 | $1.44M | -79.0% |
| 2010 | $6.86M | +315.3% |
| 2009 | -$3.19M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2018 | -$1.25M | -185.9% | -608.5% |
| June 30, 2018 | -$177.0K | -121.2% | -110.9% |
| March 31, 2018 | $1.63M | +103.4% | +11.6% |
| September 30, 2017 | $1.46M | +246.0% | +74.9% |
| June 30, 2017 | $835.0K | +788.3% | +4.2% |
| March 31, 2017 | $801.0K | +413.5% | +89.8% |
| September 30, 2016 | $422.0K | -62.1% | +348.9% |
| June 30, 2016 | $94.0K | -91.5% | -39.7% |
- Protalix BioTherapeutics, Inc. showed an increase of +400.7% in Gross Profit compared to the prior fiscal year.
- Over the 2009–2017 period, Protalix BioTherapeutics, Inc.’s gross profit has grown by 225.9% (from -$3.19 million to $4.01 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2017 report (Form 10-K), filed with the SEC on March 6, 2018.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: